NCT07302178Not yet recruiting
Combined Bitter Melon Extract and Snakehead Fish Powder Supplementation for Glycemic Control in Type 2 Diabetes
Effect of Combined Bitter Melon (Momordica Charantia L.) Extract and Snakehead Fish (Channa Striata) Powder Supplementation on Glycemic Status in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
Type 2 diabetes mellitus (T2DM) remains a major global health problem due to its high prevalence, long-term complications, and substantial economic burden. Conventional antidiabetic therapies, including insulin and oral hypoglycemic agents, may cause significant side effects during long-term use and are contraindicated in certain clinical conditions. Therefore, safe and effective herbal-based alternatives are needed. Previous preclinical and early clinical studies have shown that bitter melon (Momordica charantia L.) and snakehead fish (Channa striata) possess antidiabetic and anti-inflammatory properties, including improvement in glucose regulation, stimulation of insulin secretion, and regeneration of pancreatic cells. However, clinical evidence on their combined use remains limited. This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effect of daily supplementation with a combination of bitter melon extract and snakehead fish powder on glycemic status in adults with Type 2 diabetes mellitus. Ninety eligible participants will be randomly assigned to a treatment group receiving 500 mg/day of the herbal combination or a placebo for 4 weeks. Glycemic status will be assessed primarily through glycated albumin (GA) levels. The findings of this study are expected to provide scientific evidence regarding the safety and efficacy of this herbal combination as a complementary antidiabetic therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 11 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 28 Feb 2026
- Lead sponsor
- Universitas Muhammadiyah Surakarta
- Diseases
- Type 2 diabetes
- NCT number
- NCT07302178
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 1 Jan 2026 to the primary completion date, 28 Feb 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Using antidiabetic medications other than metformin, or unable/unwilling to comply with study procedures.
Other illness
- Allergy to snakehead fish powder (Channa striata) or bitter melon extract (Momordica charantia).
Lab values
- Pregnant or breastfeeding; or having impaired kidney or liver function (serum creatinine \> 1.5 mg/dL; SGOT/SGPT \> 2× upper limit).
Who the study is looking for
- Diagnosed with Type 2 Diabetes Mellitus (DMT2).
- Fasting plasma glucose ≥ 126 mg/dL and ≤ 200 mg/dL or random blood glucose between 200-300 mg/dL.
- Age 20-65 years
- Duration of diabetes 0-15 years.
- Currently using one class of oral antidiabetic medication (biguanide: metformin).
- Willing to participate and sign written informed consent.
Age in the registry: 20 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.